MacroGenics adds two oncology executives to its board

MacroGenics, Inc. (NASDAQ: MGNX) announced the appointments of Emil Kuriakose, M.D., and Michael Vasconcelles, M.D., as independent directors to its board of directors, effective October 30, 2026, according to a company statement.

Kuriakose brings more than a decade of biopharmaceutical experience in oncology and metabolic disease. He most recently served as Chief Medical Officer of Terns Pharmaceuticals, where he led clinical and regulatory strategy. He previously held senior roles at Calithera Biosciences and Novartis Oncology, contributing to the development and approval of panobinostat for multiple myeloma. He currently serves as an Entrepreneur in Residence at NextBio Capital and as Founder and Principal of Kure Consulting Services.

Vasconcelles has approximately 35 years of experience in academic medicine, oncology research and executive leadership. He most recently served as Head of Research and Development at Day One Biopharmaceuticals. Prior roles include Executive Vice President and Head of Research, Development and Medical Affairs at ImmunoGen, Chief Medical Officer at Flatiron Health and Unum Therapeutics, and Global Head of the Oncology Therapy Area Unit at Takeda Pharmaceuticals. He currently serves as an independent director of Molecular Partners AG and Kura Oncology, Inc.

"Both bring extensive oncology drug development experience, including leadership across clinical development, regulatory strategy and portfolio management," said Eric Risser, President and Chief Executive Officer of MacroGenics.

You May Also Be Interested In

• BNB Standard adds Anthony Scaramucci to its board of directors
• SiriusPoint names ex-Progressive CFO John Sauerland to its board
• DXP Enterprises acquires Michigan distributor MDS for $19M in sales